December 2024 | Hematology, Transfusion and Cell Therapy

Advanced Search

Share

English

Português

Home December 2024

Hematology, Transfusion and Cell Therapy

Hematology, Transfusion and Cell Therapy

ISSN: 2531-1379

Hematology, Transfusion and Cell Therapy is a quarterly scientific publication of the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), Associazione Italo-Brasiliana di Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG), and Sociedade Brasileira de Oncologia Pediátrica (SOBOPE).

Hematology, Transfusion and Cell Therapy publishes original articles, review articles and case reports covering various areas in the field of hematology and hemotherapy. The journal was previously published, until 2016, as Revista Brasileira de Hematologia e Hemoterapia.

ISSN print: 2531-1379
ISSN online: 2531-1387

Published by Elsevier Editora Ltda, Rio de Janeiro, Brazil.

See more

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), PubMed Central (PMC), Emerging Sources Citation Index (ESCI), SCImago Journal Rank (SJR), SNIP

See more

Follow us

Alert

Newsletter

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

1.6

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2025

2.2

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2025

0.370

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2025

0.619

Time to first decision

The median number of days it takes for an article to go from submission to first editorial decision.

See more

Time to first decision

33 days

View more metrics

Open Access Option

Journal Information

Previous Issue | Next Issue

Issue

Cover Vol. 46. Issue S7.

Vol. 46. Issue S7.

Hematology Specialist Association 18. National Congress

Pages S1-S78 (December 2024)

Z-EMATOLOGY IN TURKEY

Birol Güvenç

Hematol Transfus Cell Ther. 2024;46 Supl 7:S1

Full text access

Share

Oral Abstracts

Hematol Transfus Cell Ther. 2024;46 Supl 7:

Full text access

Share

Poster Abstracts

Hematol Transfus Cell Ther. 2024;46 Supl 7:

Full text access

Share

Speech Summaries

Hematol Transfus Cell Ther. 2024;46 Supl 7:

Full text access

Share

OPTIMIZATION OF IMID-BASED THERAPIES

Murat Çınarsoy

Hematol Transfus Cell Ther. 2024;46 Supl 7:S1

Full text access

Share

ATYPICAL HEMOLYTIC UREMIC SYNDROME DIAGNOSIS AND TREATMENT

Atakan Turgutkaya

Hematol Transfus Cell Ther. 2024;46 Supl 7:S2

Full text access

Share

INNOVATIONS IN AL AMYLOIDOSIS MANAGEMENT

Hande Oğul Sücüllü

Hematol Transfus Cell Ther. 2024;46 Supl 7:S2-S3

Full text access

Share

CAR-T CELL THERAPY IN LYMPHOMAS: EXPANSİON OF INDICATIONS AND NEW APPROACHES

Ayfer Gedük

Hematol Transfus Cell Ther. 2024;46 Supl 7:S3

Full text access

Share

PROFESSOR DOCTOR SEREF INCEMAN'S BIOGRAPHY AND LEGACY

Tanju Atamer

Hematol Transfus Cell Ther. 2024;46 Supl 7:S3-S4

Full text access

Share

SICKLE CELL DISEASE UPDATE: NEW TREATMENTS

Utku Aygüneş

Hematol Transfus Cell Ther. 2024;46 Supl 7:S4

Full text access

Share

PNH TREATMENT: TREATMENTS OF TODAY AND TOMORROW

Zeynep Tuğba Güven

Hematol Transfus Cell Ther. 2024;46 Supl 7:S4

Full text access

Share

NOVEL TARGETS AND THERAPIES IN MULTIPLE MYELOMA

Meral Uluköylü Mengüç

Hematol Transfus Cell Ther. 2024;46 Supl 7:S4-S5

Full text access

Share

NOVEL MAINTENANCE THERAPIES IN ACUTE MYELOID LEUKEMIA: PROLONGING REMISSION AND IMPROVING OUTCOMES

Cumali Yalçın

Hematol Transfus Cell Ther. 2024;46 Supl 7:S5

Full text access

Share

ADVANCES IN THALASSEMIA MANAGEMENT AND CHELATION THERAPY

Barbaros Şahin Karagün

Hematol Transfus Cell Ther. 2024;46 Supl 7:S5-S6

Full text access

Share

PRECISION MEDICINE IN CLL: TREATMENT BASED ON MOLECULAR PROFILES

Esra Terzi Demirsoy

Hematol Transfus Cell Ther. 2024;46 Supl 7:S6-S7

Full text access

Share

NEW GENERATION BTK INHIBITORS AND RESISTANCE IN CLL TREATMENT

Aysun Gönderen

Hematol Transfus Cell Ther. 2024;46 Supl 7:S7

Full text access

Share

THE HYPOXIA INDUCIBLE FACTOR (HIF) PATHWAY IN AML: THERAPEUTIC TARGETING

Büşra Tuğçe Akman

Hematol Transfus Cell Ther. 2024;46 Supl 7:S7-S8

Full text access

Share

TARGETED THERAPIES IN AML: CURRENT AND FUTURE TRENDS

Burcu Altındağ Avcı

Hematol Transfus Cell Ther. 2024;46 Supl 7:S8

Full text access

Share

HEMOPHILIA: ADVANCES IN TREATMENTS

Nurgül Karakaya

Hematol Transfus Cell Ther. 2024;46 Supl 7:S8-S9

Full text access

Share

OPTIMIZATION OF FIXED DURATION TREATMENT OPTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: CURRENT DATA AND FUTURE DIRECTIONS

Aslıhan Sezgin

Hematol Transfus Cell Ther. 2024;46 Supl 7:S9

Full text access

Share

OPTIMISATION OF THERAPEUTIC APPROACHES FOR HIGH-RISK ALL SUBTYPES

Cemaleddin Ozturk

Hematol Transfus Cell Ther. 2024;46 Supl 7:S9-S10

Full text access

Share

IMMUNOTHERAPY IN ALL: MONOCLONAL ANTIBODIES AND BEYOND

Fatma Arıkan

Hematol Transfus Cell Ther. 2024;46 Supl 7:S10

Full text access

Share

CAR-T CELL THERAPY IN ACUTE LEUKEMIAS

Serhat Çelik

Hematol Transfus Cell Ther. 2024;46 Supl 7:S10-S11

Full text access

Share

PRECISION MEDICINE IN MULTIPLE MYELOM

Elif Aksoy

Hematol Transfus Cell Ther. 2024;46 Supl 7:S11-S12

Full text access

Share

SUPPORTIVE CARE AND QUALITY OF LIFE IN MDS: ESSENTIAL MANAGEMENT STRATEGIES

Metban Mastanzade

Hematol Transfus Cell Ther. 2024;46 Supl 7:S12

Full text access

Share

HARMONIZATION OF TREATMENT APPROACHES: DRAWING INSPIRATION FROM PEDIATRIC TREATMENTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY

Ferda Can

Hematol Transfus Cell Ther. 2024;46 Supl 7:S12-S13

Full text access

Share

ONGOING CLINICAL TRIALS IN MULTIPLE MYELOMA

Hatice Zeynep Dikici

Hematol Transfus Cell Ther. 2024;46 Supl 7:S13

Full text access

Share

MONOCLONAL ANTIBODIES

Zekeriya Aksöz

Hematol Transfus Cell Ther. 2024;46 Supl 7:S14

Full text access

Share

ANTI-CD38 MONOCLONAL ANTIBODIES: TRANSFORMING MULTIPLE MYELOMA TREATMENT

Cem Selim

Hematol Transfus Cell Ther. 2024;46 Supl 7:S14-S15

Full text access

Share

EXPANSION OF INDICATIONS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): CURRENT STATUS AND FUTURE DIRECTIONS

Ali Eser

Hematol Transfus Cell Ther. 2024;46 Supl 7:S15

Full text access

Share

MANAGEMENT OF INHIBITORS IN HEMOPHILIA

Gaye Kalacı Katayıfçı

Hematol Transfus Cell Ther. 2024;46 Supl 7:S15-S16

Full text access

Share

ADVANCES IN THE ASSESSMENT OF MINIMAL RESIDUAL DISEASE (MRD) IN ALL

Mehmet Bakırtaş

Hematol Transfus Cell Ther. 2024;46 Supl 7:S16

Full text access

Share

CHANGING IMAGE OF TKIS: ORIGINAL, BIOSIMILAR AND GENERIC OPTIONS

Cenk Sunu

Hematol Transfus Cell Ther. 2024;46 Supl 7:S17

Full text access

Share

OPTIMIZATION OF TKI SELECTION IN CML: BALANCING EFFICACY, SAFETY, AND PATIENT PREFERENCES

Emel İşleyen Kaya

Hematol Transfus Cell Ther. 2024;46 Supl 7:S17-S18

Full text access

Share

THE EVOLVING ROLE OF PROTEASOME INHIBITORS IN CANCER TREATMENT

Alpay Yeşilaltay

Hematol Transfus Cell Ther. 2024;46 Supl 7:S18

Full text access

Share

IMPROVING TREATMENT OPTIONS IN POLYCYTHEMIA VERA: FROM INTERFERON TO NEW AGENTS

Can Özlü

Hematol Transfus Cell Ther. 2024;46 Supl 7:S18-S19

Full text access

Share

TREATMENT OF MYELOFIBROSIS: PRESENT AND FUTURE

Birsen Sahip Yesiralioğlu

Hematol Transfus Cell Ther. 2024;46 Supl 7:S19

Full text access

Share

CAR-T CELL THERAPY IN CLL

Selver Kurt

Hematol Transfus Cell Ther. 2024;46 Supl 7:S20

Full text access

Share

PHARMACOVİGİLANCE OF DRUG-INDUCED LEUKEMİA: A DESCRİPTİVE STUDY OF FDA ADVERSE EVENT REPORTİNG SYSTEM FROM 1969-2024

Ahmet Sarici, Lokman Hekim Tanriverdi

Hematol Transfus Cell Ther. 2024;46 Supl 7:S21

Full text access

Share

MANAGEMENT OF BLEEDING IN A PATIENT WITH ACQUIRED HAEMOPHILIA A: A CASE REPORT

Mihriban Yıldırım, Muzaffer Keklik, Şerife Emre Ünsal, Nesibe Taşer Kanat, Hacı Ahmet Aslaner, Gülşah Akyol, Neslihan Mandacı Şanlı, Ali Ünal

Hematol Transfus Cell Ther. 2024;46 Supl 7:S22-S23

Full text access

Share

NEWLY DIAGNOSED HEREDITARY FACTOR V DEFICIENCY IN A PATIENT PRESENTING WITH DEEP VEIN THROMBOSIS: A Rare Case

Songül Beskisiz Dönen, Vehbi Demircan, Abdullah Karakuş, Mehmet Orhan Ayyıldız

Hematol Transfus Cell Ther. 2024;46 Supl 7:S23-S24

Full text access

Share

EVALUATION OF THE IMPACT OF DEMOGRAPHIC DATA AND CLINICOPATHOLOGICAL RISK FACTORS ON TREATMENT RESPONSE AND SURVIVAL IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE-CENTER EXPERIENCE

Bulut Sat, Şendağ Yaslıkaya, Ertuğrul Bayram, Berksoy Şahin

Hematol Transfus Cell Ther. 2024;46 Supl 7:S24-S25

Full text access

Share

RICHTER TRANSFORMATION OF CLL DISEASE: A CASE REPORT WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT

Eldane Memmedova, Neslihan Mandacı Şanlı, Ali Ünal

Hematol Transfus Cell Ther. 2024;46 Supl 7:S25

Full text access

Share

A TALE OF THE CRUMBLING AMYLOID WALL: BREAKING THROUGH LIVER STIFFNESS IN AL AMYLOIDOSIS

Metban Mastanzade, Bilger Çavuş, Sevgi Kalayoğlu Beşişik

Hematol Transfus Cell Ther. 2024;46 Supl 7:S26

Full text access

Share

A SINGLE-CENTER REAL-LIFE EXPERIENCE WITH FIRST-LINE DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (DARA-VCD) IN AL AMYLOIDOSIS

Metban Mastanzade, Meryem Merve Ören Çelik, Simge Erdem, Mustafa Murat Özbalak, İpek Yönal Hindilerden, Mustafa Nuri Yenerel, Sevgi Kalayoğlu Beşışık

Hematol Transfus Cell Ther. 2024;46 Supl 7:S26-S27

Full text access

Share

FROM MULTIPLE MYELOMA TO ACUTE MYELOID LEUKEMIA

Sevde Yazıcı Şahin, Büşra Özbek, Haşim Atakan Erol, Esra Terzi Demirsoy, Ayfer Gedük, Özgür Mehtap, Pınar Tarkun, Abdullah Hacıhanifioğlu

Hematol Transfus Cell Ther. 2024;46 Supl 7:S27-S28

Full text access

Share

CASE REPORT: SIMULTANEOUS OCCURRENCE OF PLASMA AND B CELL MALIGNANCY

Nigar Abdullayeva, Damla Cagla Patır, Selin Kır, Ali Yılmazer, Derya Demir, Mehmet Soylu, Mahmut Töbü

Hematol Transfus Cell Ther. 2024;46 Supl 7:S28

Full text access

Share

THE PROGNOSTIC ROLE OF WHOLE BLOOD VISCOSITY AND BONE MARROW FIBROSIS IN PREDICTING SURVIVAL OUTCOMES IN NEW DIAGNOSIS MULTIPLE MYELOMA PATIENTS

Mustafa Duran

Hematol Transfus Cell Ther. 2024;46 Supl 7:S29

Full text access

Share

SURVIVAL OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMA PATIENTS

Elif Yıldız, Güven Çetin, Özge Pasin

Hematol Transfus Cell Ther. 2024;46 Supl 7:S29-S31

Full text access

Share

RESULTS OF UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

Muhammed Murati, Yakup Ünsal, Güler Delibalta, Serdar Bedii Omay

Hematol Transfus Cell Ther. 2024;46 Supl 7:S31

Full text access

Share

Loading more articles...

Idiomas

Hematology, Transfusion and Cell Therapy